Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...

The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that ...

Scientists have found naturally occurring compound that can stop critical process linked to the progression of some cancers ...

ENHANZE is based on Halozyme’s proprietary recombinant human hyaluronidase rHuPH20, which works locally and transiently to depolymerize hyaluronan (HA) in the extracellular matrix of the SC ...

Blue Cross Blue Shield of Michigan said it is evaluating any potential updates to the coverage process for Darzalex Faspro ...

Medindia neither buys nor sells drugs. Hyaluronidase (Facidase (1500 iu)) is an enzyme, prescribed as an adjuvant in subcutaneous fluid administration for achieving hydration, dispersion and ...

The cornerstone of Halozyme’s technology is pegvorhyaluronidase alfa, a proprietary pegylated recombinant human hyaluronidase that degrades hyaluronan (HA), a glycosaminoglycan of repeating ...

These days, an injectable dermal filler is the most often used method of lip augmentation. The most common fillers contain ...

Merck's newly developed injected version of its blockbuster cancer drug, Keytruda, may be at the center of a potential patent ...